Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).

Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N

Open source

DOI: 10.1177/17588359251344010
Published: 2025
Container: Therapeutic advances in medical oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/17588359251344010,
  title = {Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).},
  author = {Ishihara M and Kawamura T and Namba Y and Takeyasu Y and Hasegawa Y and Sato Y and Negi Y and Oba T and Sumi T and Hirata H and Funabashi H and Oya Y and Kikuchi H and Katsurada N and Nakatani T and Tanimura K and Nakagawa T and Takeda N and Asami T and Honjo O and Nagashima H and Yamaura T and Hata N and Kitazono M and Nishioka N and Tamiya A and Sakamori Y and Shigaki R and Kaira K and Honda R and Matsui T and Suzuki E and Ito K and Otsuka K and Takase N and Murakami Y and Matsuno K and Inoue S and Kisohara A and Kusumoto S and Aoshima H and Kakizaki Y and Kubo A and Hata A and Ishikawa N and Hamai K and Kanaji N and Misumi T and Matsutani N and Seki N},
  year = {2025},
  journal = {Therapeutic advances in medical oncology},
  doi = {10.1177/17588359251344010},
  url = {https://doi.org/10.1177/17588359251344010}
}

RIS

TY  - JOUR
TI  - Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
AU  - Ishihara M
AU  - Kawamura T
AU  - Namba Y
AU  - Takeyasu Y
AU  - Hasegawa Y
AU  - Sato Y
AU  - Negi Y
AU  - Oba T
AU  - Sumi T
AU  - Hirata H
AU  - Funabashi H
AU  - Oya Y
AU  - Kikuchi H
AU  - Katsurada N
AU  - Nakatani T
AU  - Tanimura K
AU  - Nakagawa T
AU  - Takeda N
AU  - Asami T
AU  - Honjo O
AU  - Nagashima H
AU  - Yamaura T
AU  - Hata N
AU  - Kitazono M
AU  - Nishioka N
AU  - Tamiya A
AU  - Sakamori Y
AU  - Shigaki R
AU  - Kaira K
AU  - Honda R
AU  - Matsui T
AU  - Suzuki E
AU  - Ito K
AU  - Otsuka K
AU  - Takase N
AU  - Murakami Y
AU  - Matsuno K
AU  - Inoue S
AU  - Kisohara A
AU  - Kusumoto S
AU  - Aoshima H
AU  - Kakizaki Y
AU  - Kubo A
AU  - Hata A
AU  - Ishikawa N
AU  - Hamai K
AU  - Kanaji N
AU  - Misumi T
AU  - Matsutani N
AU  - Seki N
PY  - 2025
JO  - Therapeutic advances in medical oncology
DO  - 10.1177/17588359251344010
UR  - https://doi.org/10.1177/17588359251344010
ER  -

APA

M, I., T, K., Y, N., Y, T., Y, H., Y, S., Y, N., T, O., T, S., H, H., H, F., Y, O., H, K., N, K., T, N., K, T., T, N., N, T., T, A., O, H., H, N., T, Y., N, H., M, K., N, N., A, T., Y, S., R, S., K, K., R, H., T, M., E, S., K, I., K, O., N, T., Y, M., K, M., S, I., A, K., S, K., H, A., Y, K., A, K., A, H., N, I., K, H., N, K., T, M., N, M., & N, S. (2025). Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).. Therapeutic advances in medical oncology. https://doi.org/10.1177/17588359251344010

Source records

pubmed · retrieved 2026-09-25T19:36:02.710Z